Administration Options

UDENYCA on-body injector

Open

UDENYCA prefilled autoinjector

Open

FIRST OF ITS KIND*
UDENYCA PREFILLED AUTOINJECTOR

User-friendly features promote successful at-home or in-office delivery

Help prevent febrile neutropenia while administering in less than 10 seconds
per cycle⁵

Help prevent febrile neutropenia while administering in less than 10 seconds per cycle²

For pegfilgrastim-product administration in the United States.

Simple administration with 2 clicks⁶

For complete administration directions, please see the Instructions for Use. Only adults can administer UDENYCA with the prefilled autoinjector.

Hold the autoinjector with the clear cap facing up and pull the cap straight off.

Press the autoinjector firmly against the skin and you will hear the first “click.”

After you hear the second “click,” continue to hold the autoinjector in place and count to 5.

See the UDENYCA autoinjector in action

For complete administration directions, please see theInstructions for Use.

Turn your phone sideways for an ideal viewing experience.

Prepare the application site

Get the device ready

Apply the injector

REVIEW IMPORTANT INFORMATION WITH YOUR PATIENT

UDENYCA prefilled syringe

Open

UDENYCA
PREFILLED SYRINGE

Tried-and-true administration delivered in office by the care team*

Next-day visits to the clinic may increase comfort for some patients

Can be left at room temperature (68°–77°) for up to 48 HOURS before being discarded

The UDENYCA prefilled syringe is not designed to allow for direct administration of doses less than 0.6 mL (6 mg), as the syringe does not bear graduation marks

Direct administration to pediatric patients weighing less than 45 kg, requiring dosing of less than 0.6 mL (6 mg), is not recommended due to the potential for dosing errors. For more information, please refer to the Prescribing Information.

Single-dose prefilled subcutaneous injection of 6 mg administered once per chemotherapy cycle

Choose the administration that works best for your patient’s individual needs

Do not administer between 14 days before and 24 hours after cytotoxic chemotherapy.²

Explore coverage by state for each UDENYCA administration option.

Use the interactive Coherus Solutions^™ Payer Coverage Tool

Supply you can count on for your patients

Since launch, over 1,000,000 doses have been introduced to the supply chain^†5

†

January 2019 through November 2023. Includes prefilled syringe and autoinjector.

ACCESS & SUPPORT

UDENYCA Solutions^TM provides patient support services designed to remove hurdles to access UDENYCA^®

Discover patient support

HELPFUL RESOURCES

Find product information, research articles, and resources to share with your patients.

Access UDENYCA Resources